From the Department of Microbiology and Infectious Diseases, Royal Women's Hospital; the Murdoch Childrens Research Institute; and the Department of Obstetrics and Gynaecology, University of Melbourne, Melbourne, Australia.
Obstet Gynecol. 2011 Jan;117(1):101-108. doi: 10.1097/AOG.0b013e3182020704.
To estimate human papillomavirus (HPV) clearance of women with cervical abnormalities after treatment.
Women attending dysplasia clinics between 2001 and 2007 with a new diagnosis of high-grade dysplasia or persistent low-grade dysplasia requiring treatment by excision or laser ablation were invited to participate. Cervical cytology, histology of biopsies collected at colposcopy, and HPV DNA detection and genotyping of 37 HPV genotypes on specimens collected at treatment and subsequent routine visits were examined. A log-rank test was used to compare the survival distribution between groups.
Of the 1,649 women eligible at treatment (baseline), 1,207 (73%) were included in the analysis; 96% (n=1,159) had three or more posttreatment visits. At baseline and the subsequent three follow-up visits, the prevalence of women with HPV DNA detected was 84%, 53% (on average, 6.3 months after baseline), 44% (on average, 15.7 months after baseline), and 45% (on average, 24.3 months after baseline). The median time to HPV clearance was approximately 6 months for either HPV 16 (n=387) or HPV 18 (n=96), irrespective of concurrent detection of other types. On average, HPV 16 or HPV 18 types cleared faster than other types (P<.001). This association remained significant after adjustment for age, preoperative histology, number of preoperative histology results, and treatment type.
Clearance times of HPV 16 and HPV 18 infections were similar to each another but shorter than other HPV types.
III.
评估治疗后宫颈异常妇女的人乳头瘤病毒（HPV）清除率。
2001 年至 2007 年间，邀请在细胞学异常门诊就诊且新诊断为高级别上皮内瘤变或需要切除或激光消融治疗的持续性低级别上皮内瘤变的女性参与研究。对阴道镜活检的宫颈细胞学、组织学以及治疗时和后续常规就诊时采集的标本中 37 种 HPV 基因型的 HPV DNA 检测和基因分型进行检查。采用对数秩检验比较组间的生存分布。
在治疗时（基线）有 1649 名符合条件的女性中，有 1207 名（73%）纳入分析；96%（n=1159）有 3 次或以上的治疗后就诊。在基线和随后的 3 次随访中，HPV DNA 检测阳性的女性比例分别为 84%、53%（平均在基线后 6.3 个月）、44%（平均在基线后 15.7 个月）和 45%（平均在基线后 24.3 个月）。HPV 清除的中位时间大约为 6 个月，无论是 HPV 16（n=387）还是 HPV 18（n=96），均与其他类型同时检测无关。HPV 16 或 HPV 18 型的平均清除速度快于其他类型（P<.001）。在校正年龄、术前组织学、术前组织学结果数量和治疗类型后，这种相关性仍然显著。
HPV 16 和 HPV 18 感染的清除时间相似，但短于其他 HPV 类型。
III。
